Wells Fargo Sees Little Chance Of Higher Bid For Kite Pharma
August 28, 2017 at 21:05 PM EDT
Gilead and Kite Pharma have announced that the companies have entered into a definitive agreement pursuant to which the former will acquire the latter for $180 per share in cash.
